Athira Pharma Acquires Lasofoxifene Development Rights, Secures $90 Million Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Globenewswire
- Financing Support: Athira Pharma has completed a $90 million private placement financing co-led by Commodore Capital and others to support the development of Lasofoxifene, which is expected to drive its clinical data release in mid-2027.
- Clinical Trial Progress: The ongoing ELAINE-3 clinical trial is over 50% enrolled, positioning Lasofoxifene to potentially become the new standard of care for ESR1-mutant metastatic breast cancer, addressing a significant market gap.
- Market Potential: The metastatic breast cancer market is projected to reach $41.7 billion by 2030, with Athira's Lasofoxifene poised to capture a significant share by meeting the needs of approximately 40% of patients.
- Strategic Importance: Athira's CEO emphasized that this acquisition marks a crucial step in the company's strategic development, aiming to enhance patient quality of life through innovative therapies while delivering lasting value for shareholders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
